Literature DB >> 15104676

Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.

V Corbière1, H Nicolay, V Russo, V Stroobant, V Brichard, T Boon, P van der Bruggen.   

Abstract

"Cancer germline" genes such as those of the MAGE family are expressed in many tumors and in male germline cells but are silent in normal tissues. They encode shared tumor-specific antigens that have been used in therapeutic vaccination trials of cancer patients. We report the identification of a new MAGE-1-encoded peptide that is recognized by a cytolytic T-lymphocyte (CTL) clone on human leukocyte antigen (HLA)-B*5701. The sequence of the peptide, corresponding to position 102-112 of the MAGE-1 protein sequence, is ITKKVADLVGF. When tumor cells expressing MAGE-1 were transfected with HLA-B*5701, they were lyzed by the CTL clone, indicating that the peptide is processed in tumor cells and can, therefore, be used as a target for anti-tumoral vaccination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15104676     DOI: 10.1111/j.0001-2815.2004.00203.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  3 in total

1.  Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Authors:  An M T Van Nuffel; Daphné Benteyn; Sofie Wilgenhof; Lauranne Pierret; Jurgen Corthals; Carlo Heirman; Pierre van der Bruggen; Pierre G Coulie; Bart Neyns; Kris Thielemans; Aude Bonehill
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

2.  Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide.

Authors:  Kok Fei Chan; Benjamin S Gully; Stephanie Gras; Dennis X Beringer; Lars Kjer-Nielsen; Jonathan Cebon; James McCluskey; Weisan Chen; Jamie Rossjohn
Journal:  Nat Commun       Date:  2018-03-12       Impact factor: 14.919

Review 3.  Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Authors:  Neftali Ortega Alarcon; Maddy Jaramillo; Heidi M Mansour; Bo Sun
Journal:  Pharmaceutics       Date:  2022-07-11       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.